News | April 28, 2023
Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Bridging the gap between histopathology and molecular pathology
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Subscribe To Our Newsletter & Stay Updated
